DexCom (NASDAQ:DXCM) Stock Unloaded Sen. Tina Smith

Senator Tina Smith (Democratic-Minnesota) recently sold shares of DexCom, Inc. (NASDAQ:DXCM). In a filing disclosed on May 10th, the Senator disclosed that they had sold between $100,001 and $250,000 in DexCom stock on May 7th.

Senator Tina Smith also recently made the following trade(s):

• Sold $100,001 – $250,000 in shares of Insulet (NASDAQ:PODD) on 5/7/2026.
• Sold $100,001 – $250,000 in shares of DexCom (NASDAQ:DXCM) on 4/29/2026.
• Sold $100,001 – $250,000 in shares of Insulet (NASDAQ:PODD) on 4/29/2026.
• Sold $50,001 – $100,000 in shares of 3M (NYSE:MMM) on 3/31/2026.
• Sold $100,001 – $250,000 in shares of Berkshire Hathaway (NYSE:BRK.B) on 3/31/2026.

DexCom Price Performance

NASDAQ DXCM traded up $3.81 on Friday, hitting $61.63. The company had a trading volume of 11,132,607 shares, compared to its average volume of 5,256,073. The company has a market capitalization of $23.78 billion, a PE ratio of 26.34, a PEG ratio of 1.00 and a beta of 1.40. The company’s fifty day moving average price is $63.46 and its 200-day moving average price is $65.89. The company has a debt-to-equity ratio of 0.42, a current ratio of 1.95 and a quick ratio of 1.64. DexCom, Inc. has a 12-month low of $54.11 and a 12-month high of $89.98.

DexCom (NASDAQ:DXCM) last issued its quarterly earnings results on Thursday, April 30th. The medical device company reported $0.56 EPS for the quarter, topping the consensus estimate of $0.47 by $0.09. The company had revenue of $1.19 billion during the quarter, compared to analyst estimates of $1.17 billion. DexCom had a net margin of 19.31% and a return on equity of 33.33%. The firm’s revenue was up 15.0% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $0.32 EPS. As a group, analysts predict that DexCom, Inc. will post 2.56 earnings per share for the current year.

Key Headlines Impacting DexCom

Here are the key news stories impacting DexCom this week:

• Positive Sentiment: DexCom outlined a 2030 growth plan calling for at least 10% annual revenue growth through 2030, along with margin targets that suggest improving profitability over time. Diabetes Tech Player DexCom Lays Out 2030 Growth Vision
• Positive Sentiment: The company authorized a new $1 billion share buyback, which can support the stock by signaling confidence in future cash flow and returning capital to shareholders. Diabetes Tech Player DexCom Lays Out 2030 Growth Vision
• Positive Sentiment: Management also highlighted next-generation products, including the G8 glucose sensor and dual-analyte sensing, which could expand DexCom’s competitive position and addressable market. Dexcom to add 2 board directors with activist investor Elliott
• Positive Sentiment: DexCom and Elliott Investment Management agreed to add two independent directors to the board and revise governance, a move that may improve oversight and strategic execution. Dexcom to appoint two directors, revamp board committee with Elliott
• Neutral Sentiment: Wall Street sentiment remains constructive overall, with a “Moderate Buy” consensus and an average price target above recent trading levels, though there are still some hold and underweight ratings in the mix. Are Wall Street analysts bullish on DexCom’s stock?
• Negative Sentiment: Director Bridgette Heller sold 1,012 shares, but the transaction was small and was made under a pre-arranged trading plan, so it is less likely to be a major negative signal. Bridgette Heller Sells 1,012 Shares of DexCom (NASDAQ:DXCM) Stock

Institutional Investors Weigh In On DexCom

A number of large investors have recently modified their holdings of the business. Gradient Investments LLC grew its holdings in shares of DexCom by 13.8% in the fourth quarter. Gradient Investments LLC now owns 332,006 shares of the medical device company’s stock valued at $22,035,000 after purchasing an additional 40,343 shares during the period. Nordea Investment Management AB grew its holdings in shares of DexCom by 118.6% in the fourth quarter. Nordea Investment Management AB now owns 254,315 shares of the medical device company’s stock valued at $16,988,000 after purchasing an additional 137,986 shares during the period. Mirae Asset Global Investments Co. Ltd. grew its holdings in shares of DexCom by 11.2% in the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 212,045 shares of the medical device company’s stock valued at $14,269,000 after purchasing an additional 21,352 shares during the period. NEOS Investment Management LLC grew its holdings in shares of DexCom by 58.7% in the third quarter. NEOS Investment Management LLC now owns 175,982 shares of the medical device company’s stock valued at $11,842,000 after purchasing an additional 65,066 shares during the period. Finally, Peterson Wealth Services grew its holdings in shares of DexCom by 423.6% in the third quarter. Peterson Wealth Services now owns 28,937 shares of the medical device company’s stock valued at $1,947,000 after purchasing an additional 23,410 shares during the period. Hedge funds and other institutional investors own 97.75% of the company’s stock.

Insider Transactions at DexCom

In other DexCom news, Director Bridgette P. Heller sold 1,012 shares of the company’s stock in a transaction dated Tuesday, May 12th. The shares were sold at an average price of $60.01, for a total value of $60,730.12. Following the transaction, the director owned 25,007 shares of the company’s stock, valued at $1,500,670.07. This represents a 3.89% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Michael Jon Brown sold 1,700 shares of the company’s stock in a transaction dated Wednesday, April 15th. The shares were sold at an average price of $63.04, for a total transaction of $107,168.00. Following the completion of the transaction, the executive vice president directly owned 111,204 shares in the company, valued at $7,010,300.16. The trade was a 1.51% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 4,412 shares of company stock valued at $278,143 in the last three months. 0.28% of the stock is currently owned by insiders.

Analyst Upgrades and Downgrades

Several equities research analysts recently commented on DXCM shares. Wells Fargo & Company cut their price target on shares of DexCom from $93.00 to $85.00 and set an “overweight” rating for the company in a report on Friday, February 13th. Raymond James Financial set a $81.00 price target on shares of DexCom in a report on Friday, May 1st. Truist Financial reissued a “buy” rating and issued a $80.00 price target (down from $82.00) on shares of DexCom in a report on Tuesday, February 17th. Citigroup reissued a “buy” rating and issued a $79.00 price target (down from $84.00) on shares of DexCom in a report on Monday, May 4th. Finally, BTIG Research reaffirmed a “buy” rating and set a $85.00 target price on shares of DexCom in a report on Monday, March 9th. Three equities research analysts have rated the stock with a Strong Buy rating, eighteen have given a Buy rating, three have assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, DexCom has an average rating of “Moderate Buy” and an average price target of $83.22.

About Senator Smith

Tina Smith (Democratic Party) is a member of the U.S. Senate from Minnesota. She assumed office on January 3, 2018. Her current term ends on January 3, 2027. Smith (Democratic Party) ran for re-election to the U.S. Senate to represent Minnesota. She won in the general election on November 3, 2020. Smith succeeded former Senator Al Franken (D). She assumed office on January 3, 2018. Smith won a full term in the special general election for the position on November 6, 2018. She defeated Karin Housley (R), Sarah Wellington (Legal Marijuana Now Party), and Jerry Trooien (Unaffiliated) to win the seat. She advanced to the general election after defeating five challengers in the special Democratic primary election on August 14, 2018. Smith previously served as the 48th lieutenant governor of Minnesota. She was elected to the position on a joint ticket with incumbent Governor Mark Dayton on November 4, 2014, and was sworn into office on January 5, 2015.

DexCom Company Profile

DexCom, Inc is a medical device company that develops, manufactures and distributes continuous glucose monitoring (CGM) systems for people with diabetes. Its products are designed to provide near real-time glucose readings, trend information and alerts to help patients and clinicians manage insulin dosing and reduce hypoglycemia and hyperglycemia. The company’s offerings combine wearable glucose sensors, wireless transmitters and software applications that deliver data to smartphones, dedicated receivers and cloud-based platforms for remote monitoring.

Founded in 1999 and headquartered in San Diego, California, DexCom has focused its business on advancing CGM technology and expanding clinical use beyond traditional insulin-dependent populations.